Trial Profile
A phase II study to evaluate safety and efficacy of combined treatment with ipilimumab and intratumoral interleukin-2 in pretreated patients with stage IV melanoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Sep 2015
Price :
$35
*
At a glance
- Drugs Aldesleukin (Primary) ; Ipilimumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Acronyms i i i
- 19 Sep 2015 Status changed from planning to completed, as reported by European Clinical Trials Database (EudraCT2010-019033-98)
- 06 Jul 2015 New trial record
- 02 Jun 2015 Based on results of a phase I trial (see trial profile 700222282), investigators at the University of Utah are planning to conduct this phase II trial of intratumoural ipilimumab and aldesleukin in conjunction with systemic immunotherapy, according to an abstract presented at ASCO 2015.